Knee Osteoarthritis Pipeline Assessment (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals | Abbvie, Amzell, AstraZeneca, BioIntegrate, Eupraxia Pharmaceuticals

Knee Osteoarthritis Pipeline Assessment (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals | Abbvie, Amzell, AstraZeneca, BioIntegrate, Eupraxia Pharmaceuticals
Delveinsight Business Research LLP
As per DelveInsight’s assessment, globally, about 40+ key pharma and biotech companies are working on 40+ pipeline drugs in the Knee Osteoarthritis therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

Knee Osteoarthritis Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Knee Osteoarthritis Market. 

The Knee Osteoarthritis Pipeline report embraces in-depth commercial, regulatory, and Knee Osteoarthritis clinical trial assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the emerging Knee Osteoarthritis drugs, including the mechanism of action, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

Knee Osteoarthritis Pipeline Analysis

Knee Osteoarthritis Pipeline Analysis

The report provides insights into: 

  • The report provides detailed insights into the emerging therapies for Knee Osteoarthritis treatment and the aggregate therapies developed by major pharma companies.

  • It accesses the different Knee Osteoarthritis therapies segmented into early-stage, mid-stage, and late-stage of clinical development.

  • It outlines the major Knee Osteoarthritis companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • The report evaluates the Knee Osteoarthritis drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Knee Osteoarthritis therapeutic market.

Analysis of Emerging Knee Osteoarthritis Therapies by Phases

The report covers the emerging products under different phases of clinical development like –

  • Late-stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I) 

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates

Route of Administration

Knee osteoarthritis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral

  • Parenteral

  • Intravenous

  • Subcutaneous

  • Topical

Molecule Type

Products have been categorized under various Molecule types such as

  • Monoclonal Antibody

  • Peptides

  • Polymer

  • Small molecule

  • Gene therapy

Learn How the Knee Osteoarthritis Treatment Outlook will Evolve with the Ongoing Clinical & Commercial Activities in the Therapeutic Market @

https://www.delveinsight.com/sample-request/knee-osteoarthritis-pipeline-insight

Knee Osteoarthritis Therapeutics Landscape

There are approx. 40+ key companies developing therapies for Knee osteoarthritis. Currently, Bone Therapeutics is leading the therapeutics market with its Knee osteoarthritis drug candidates in the most advanced stage of clinical development.

 

“On 13 June 2023, Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (TSX: EPRX) announced that the U.S. Food and Drug Administration (“FDA”) has granted Fast Track designation for the investigation of EP-104IAR in the treatment of adults with osteoarthritis (“OA”) of the knee.”

 

Knee Osteoarthritis Companies Actively Working in the Therapeutic Market Include:

Abbvie, Akan Biosciences, Ampio Pharmaceuticals, Amzell, Anika Therapeutics, AstraZeneca, BioIntegrate, Bioventus LLC, Bone Therapeutics, CAR-T (Shanghai) Biotechnology, Celltex Therapeutics Corporation, Centrexion Therapeutics, Eli Lilly and Company, Eupraxia Pharmaceuticals, Flexion Therapeutics, Galapagos NV, Gwo Xi Stem Cell Applied Technology, Meluha Life Sciences SDN BHD, Mestex AG, Mitsubishi Tanabe Pharma Corporation, Moebius Medical, Novartis, Orient Europharma Co., Ltd., OrthoTrophix, Paradigm Biopharmaceuticals, Peptinov SAS, Personalized Stem Cells, Propella Therapeutics, PT. Prodia Stem Cell Indonesia, Purdue Pharma, R-Bio, Regeneron Pharmaceuticals, Samumed LLC, Sclnow Biotechnology, Sorrento Therapeutics, Swiss Medica XXI Century S.A., Taiwan Liposome Company, Techfields Pharma, UnicoCell Biomed CO. LTD, Vivex Biomedical, Xalud Therapeutics, Yooyoung Pharmaceutical, and many others.

Emerging and Marketed Knee Osteoarthritis Drugs Covered in the Report Include:

  • JTA-004: Bone Therapeutics

  • MM-II: Moebius Medical

And Many More

Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Knee Osteoarthritis Companies Working in the Market @ 

https://www.delveinsight.com/sample-request/knee-osteoarthritis-pipeline-insight

Table of Content (TOC)

1. Report Introduction

2. Executive Summary

3. Knee Osteoarthritis Treatment Patterns

4. Knee Osteoarthritis – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Knee Osteoarthritis Late Stage Products (Phase-III)

7. Knee Osteoarthritis Mid-Stage Products (Phase-II)

8. Knee Osteoarthritis Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Knee Osteoarthritis Discontinued Products

13. Knee Osteoarthritis Product Profiles

14. Major Knee Osteoarthritis Companies in the Market

15. Key Products in the Knee Osteoarthritis Therapeutics Segment

16. Dormant and Discontinued Products

17. Knee Osteoarthritis Unmet Needs

18. Knee Osteoarthritis Future Perspectives

19. Knee Osteoarthritis Analyst Review  

20. Appendix

21. Report Methodology

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF to Explore the Key Offerings of the Report @ 

https://www.delveinsight.com/sample-request/knee-osteoarthritis-pipeline-insight

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

 

Other Trending Healthcare Reports By DelveInsight

Cardiac Monitoring System Market

“Cardiac Monitoring System Market Insight, Competitive Landscape, and Market Forecast, 2028” report delivers an in-depth understanding of historical and forecasted Cardiac Monitoring System market size, share, and trends globally, which comprises North America, Europe, APAC, and RoW. Moreover, it covers the key companies, emerging products, and commercial & regulatory development, in the Cardiac Monitoring System Market.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/